Director at $RXT sells 1,780,619 shares in insider sale

Insider Sale: Director at $RXT Unloads 1,780,619 Shares

A recent SEC filing revealed that Amar Maletira, a director at $RXT, disposed of 1,780,619 company shares on September 15, 2025, netting roughly $2,403,835. This transaction represented the sale of about 27.9% of Maletira’s shares of this particular class of stock, leaving them with a remaining ownership of 4,608,619 shares in this class of $RXT stock.

$RXT Insider Trading Insights

Over the past half-year, $RXT insiders engaged in two transactions involving $RXT stock on the open market. Notably, all transactions were sales, with no purchases recorded. Amar Maletira’s sale of 1,780,619 shares for an estimated $2,403,835 and Anthony Scott’s sale of 40,000 shares for roughly $57,200 dominated the insider trading activities in recent months.

Tracking insider transactions can offer valuable insights into a company’s performance and future prospects.

$RXT Hedge Fund Activity

The latest quarter saw 55 institutional investors augment their holdings of $RXT stock, while 59 reduced their positions in the company. Notable moves during this period include Apollo Management Holdings, L.P.’s addition of 129,609,000 shares (+100.0%) to their portfolio in the second quarter of 2025, amounting to an estimated $165,899,520.

Conversely, Mackenzie Financial Corp removed 2,184,821 shares (-97.0%) from their portfolio in the same period, resulting in an estimated loss of $2,796,570. Other major players, such as BlackRock, Inc., GSA Capital Partners LLP, and Renaissance Technologies LLC, also made significant adjustments to their $RXT holdings.

$RXT Analyst Ratings

In recent reports on $RXT, Wall Street analysts issued no buy ratings and one sell rating. On April 25, 2025, Barclays issued an “Underweight” rating, indicating a cautious outlook on the stock.

Monitoring analyst ratings can provide investors with additional perspectives on the expected performance of a particular stock.

$RXT Price Targets

Various analysts have assigned price targets to $RXT in the past six months. Among the four analysts who offered price targets for the stock, the median target stood at $1.65. Noteworthy targets include Keith Bachman’s $1.4 target set on August 12, 2025, Daniel Perlin’s $2.0 target from May 12, 2025, and Kevin Mcveigh’s $1.9 target from May 9, 2025.

It’s important for investors to consider these price targets as they evaluate their investment decisions.

In conclusion, it’s crucial for investors to stay informed about insider trading activities, hedge fund movements, analyst ratings, and price targets to make well-informed investment decisions. Conducting thorough research and monitoring these key aspects can aid in understanding a company’s financial health and potential future performance.